Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis, Role of Immunosenescence

  • Dema, María|||0000-0003-4812-4304
  • Eixarch, Herena|||0000-0001-7525-9533
  • Hervera Abad, Arnau|||0000-0001-8362-369X
  • Castillo Juárez, Mireia|||0000-0001-8979-3219
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Montalban, Xavier|||0000-0002-0098-9918
  • Espejo, Carmen|||0000-0001-9949-5901
The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability accumulation. This phenomenon can be related to age-related changes in the immune system: with age, the immune system undergoes a process called immunosenescence, characterized by a decline in the function of both the innate and adaptive immune responses. This decline can lead to a decreased ability to control inflammation and repair damaged tissue. Additionally, older individuals often experience a shift toward a more pro-inflammatory state, known as inflammaging, which can exacerbate the progression of neurodegenerative diseases like MS. Therefore, age-related alterations in the immune system could be responsible for the difference in the phenotype of MS observed in older and younger patients. In this study, we investigated the effects of age on the immunopathogenesis of experimental autoimmune encephalomyelitis (EAE). Our findings indicate that EAE is more severe in aged mice due to a more inflammatory and neurodegenerative environment in the central nervous system. Age-related changes predominantly affect adaptive immunity, characterized by altered T cell ratios, a pro-inflammatory Th1 response, increased regulatory T cells, exhaustion of T cells, altered B cell antigen presentation, and reduced NK cell maturation and cytotoxicity. Transcriptomic analysis reveals that fewer pathways and transcription factors are activated with age in EAE. These findings allow us to identify potential therapeutic targets specific to elderly MS patients and work on their development in the future.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Multiple sclerosis, molecular pathogenesis and therapeutic intervention

  • Boutitah-Benyaich, Imane
  • Eixarch, Herena|||0000-0001-7525-9533
  • Villacieros-Álvarez, Javier
  • Hervera Abad, Arnau|||0000-0001-8362-369X
  • Cobo-Calvo, Álvaro|||0000-0002-2574-0721
  • Montalban, Xavier|||0000-0002-0098-9918
  • Espejo, Carmen|||0000-0001-9949-5901
Multiple sclerosis is a chronic immune-mediated disorder of the central nervous system characterized by demyelination, axonal loss, and neuroinflammation, culminating in progressive neurological disability. Despite significant advances in understanding its immunopathogenesis, current immunotherapies remain limited in their ability to halt disease progression, making multiple sclerosis incurable and highlighting the critical need for novel therapeutic strategies. Antigen-specific immunotherapy represents a groundbreaking approach that aims to restore immune tolerance to myelin-derived antigens while preserving the protective functions of the immune system. Unlike broad immunosuppressive strategies, antigen-specific immunotherapy offers the potential for highly targeted modulation of pathogenic immune responses, reducing off-target effects and enhancing safety profiles. Over the last two decades, preclinical studies and clinical trials have explored diverse antigen-specific immunotherapy modalities, ranging from peptide-based vaccines to nanoparticle platforms, each aimed at achieving durable tolerance in multiple sclerosis. This review provides a comprehensive overview of multiple sclerosis, covering its etiology, clinical features, pathogenesis, pathology, and current therapeutic approaches. Thus, it delves into the current state of antigen-specific immunotherapy research, critically examining its successes and limitations while addressing the translational challenges that must be overcome to realize its therapeutic potential. By integrating insights from immunology, biotechnology, and translational medicine, we propose directions for advancing antigen-specific approaches in the quest for transformative multiple sclerosis therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reprogramming autoimmunity, inducing antigen-specific tolerance via apoptotic mimicry in an experimental model of multiple sclerosis

  • Eixarch, Herena|||0000-0001-7525-9533
  • Boutitah-Benyaich, Imane
  • Plaza, Jorge
  • Rodríguez-Vidal, Sílvia
  • Salvadó, Míriam
  • Mancera-Arteu, Montserrat
  • Almenara-Fuentes, Lidia|||0000-0002-8518-8078
  • Dalmases, Martí
  • Vives Pi, Marta|||0000-0003-3735-0779
  • Montalban, Xavier|||0000-0002-0098-9918
  • Barneda Zahonero, Bruna|||0000-0002-6557-5222
  • Espejo, Carmen|||0000-0001-9949-5901
Multiple sclerosis (MS) is an immune-mediated disorder characterized by demyelination, axonal damage, and neurodegeneration, leading to neurological disability in patients. It is considered a prototypic antigen-specific autoimmune disease, and therefore is a strong candidate for therapies aimed at restoring immune tolerance to self-antigens. However, the development of effective antigen-specific tolerization remains an important unmet medical need. In the present study, we administered phosphatidylserine (PS) liposomes, mimicking apoptotic bodies, containing a myelin antigen [35-55 myelin oligodendrocyte glycoprotein (MOG) peptide] in the MOG-induced experimental autoimmune encephalomyelitis (EAE), as a therapeutic strategy for the treatment of MS. MOG PS liposomes or empty PS liposomes were administered in a single administration before or after the appearance of EAE neurological symptoms. Intraperitoneal, intranasal, intradermal and intravenous administration routes were used. For mechanistic studies, peripheral T and B cell subpopulations of treated EAE mice were studied by flow cytometry. In addition, EAE mice treated with MOG PS liposomes received blocking antibodies to deplete Treg, B cells, and immunomodulatory mediators IL-10 and TGF-β. The efficacy of the therapy was compared with daily administration of fingolimod. We demonstrated the therapeutic efficacy of the MOG-loaded PS liposomes when administered intraperitoneally before onset, and the mechanism of action of MOG-loaded PS liposomes involved Treg and B cells, since blocking these populations and their related molecules IL-10 and TGF-β, abrogated the tolerogenic effect of the therapy. We also demonstrated the therapeutic efficacy of the MOG-loaded PS liposomes when administered intraperitoneally after appearance of EAE neurological signs. Alternative routes of administration such as intravenous and intradermal, which are more suited for translation in clinical trials, were found to be efficacious before and after appearance of EAE neurological signs. Intravenous administration of MOG-loaded PS liposomes in established EAE reduced dendritic cell activation, decreased inflammatory cytokine secretion, induced T cell exhaustion and expanded regulatory B cells (Breg) and CD39 + CD4 + FoxP3 + T cells. Our findings indicate that antigen-specific therapy with PS liposomes mimicking apoptotic bodies downregulates the MOG-specific inflammatory immune response and expands Breg and Treg cells, offering a safe, versatile, and easily applicable approach that strongly supports its potential for near-future clinical translation in MS. The online version contains supplementary material available at 10.1186/s12974-025-03618-w.